Reyataz

Reyataz is a brand name of atazanavir, approved by the FDA in the following formulation(s):

REYATAZ (atazanavir sulfate - capsule; oral)

• 
  Manufacturer: BRISTOL MYERS SQUIBB
  
  Approval date: June 20, 2003
  
  Strength(s): EQ 100MG BASE, EQ 150MG BASE, EQ 200MG BASE
  


• 
  Manufacturer: BRISTOL MYERS SQUIBB
  
  Approval date: October 16, 2006
  
  Strength(s): EQ 300MG BASE ^[RLD]

Has a generic version of Reyataz been approved?

No. There is currently no therapeutically equivalent version of Reyataz available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Reyataz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Antivirally active heterocyclic azahexane derivatives
  Patent 5,849,911
  Issued: December 15, 1998
  Inventor(s): Fassler; Alexander & Bold; Guido & Capraro; Hans-Georg & Lang; Marc & Khanna; Satish Chandra
  Assignee(s): Novartis Finance Corporation
  There are described compounds of formula I*, ##STR1## wherein R.sub.1 is lower alkoxycarbonyl, R.sub.2 is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl, R.sub.3 is phenyl that is unsubstituted or substituted by one or more lower alkoxy radicals, or C.sub.4 -C.sub.8 cycloalkyl, R.sub.4 is phenyl or cyclohexyl each substituted in the 4-position by unsaturated heterocyclyl that is bonded by way of a ring carbon atom, has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected from nitrogen, oxygen, sulfur, sulfinyl (--SO--) and sulfonyl (--SO.sub.2 --) and is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl, R.sub.5, independently of R.sub.2, has one of the meanings mentioned for R.sub.2, and R.sub.6, independently of R.sub.1, is lower alkoxycarbonyl, or salts thereof, provided that at least one salt-forming group is present. The compounds are inhibitors of retroviral aspartate protease and can be used, for example, in the treatment of AIDS. They exhibit outstanding pharmacodynamic properties.
  
  Patent expiration dates:
  
  
  • June 20, 2017
    
    ✓ 
    Patent use: METHOD FOR TREATING HIV-1 INFECTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Bisulfate salt of HIV protease inhibitor
  Patent 6,087,383
  Issued: July 11, 2000
  Inventor(s): Singh; Janak & Pudipeddi; Madhusudhan & Lindrud; Mark D.
  Assignee(s): Bristol-Myers Squibb Company
  The present invention provides the crystalline bisulfate salt of the formula ##STR1## which is found to have unexpectedly high solubility/dissolution rate and oral bioavailability relative to the free base form of this azapeptide HIV protease inhibitor compound.
  
  Patent expiration dates:
  
  
  • December 21, 2018
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 25, 2011 - NEW PATIENT POPULATION
  
  
  • September 30, 2011 - ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS
  
  
  • February 4, 2014 - DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
  
  

See also...

• Reyataz Consumer Information (Drugs.com)
• Reyataz Consumer Information (Wolters Kluwer)
• Reyataz Consumer Information (Cerner Multum)
• Reyataz Advanced Consumer Information (Micromedex)
• Reyataz AHFS DI Monographs (ASHP)
• Atazanavir Consumer Information (Wolters Kluwer)
• Atazanavir Consumer Information (Cerner Multum)
• Atazanavir Advanced Consumer Information (Micromedex)
• Atazanavir Sulfate AHFS DI Monographs (ASHP)